2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148820
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
    		98.65%
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT (Formula V) is a agent-linker conjugate that composed of a potent topoisomerase I inhibitor and a linker to make an antibody agent conjugate (ADC), ABBV-969.
    Br-Val-Ala-NH2-bicyclo[1.1.1]pentane-7-MAD-MDCPT
  • HY-145399
    AZ14170133
    		98.78%
    AZ14170133 (SG 3932) is a Drug-Linker Conjugates for ADC, which comprises a topoisomerase inhibitor and a linker for ligand unit connecting. AZ14170133 can be used to synthesis antibody-drug conjugate (ADC).
    AZ14170133
  • HY-147271
    Mal-PEG8-Val-Ala-PAB-Exatecan
    		99.48%
    Mal-PEG8-Val-Ala-PAB-Exatecan (Compound 9b) is an antibody-drug conjugate linker (ADC linker) that binds to Nectin-4 polypeptides conjugated to chemotherapeutic agents. Mal-PEG8-Val-Ala-PAB-Exatecan can be used for cancer research.
    Mal-PEG8-Val-Ala-PAB-Exatecan
  • HY-12460
    SPDB-DM4
    		98.35%
    SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, a tubulin inhibitor) via a SPDB linker, exhibiting potent anti-tumor activity.
    SPDB-DM4
  • HY-126682
    Mal-VC-PAB-DM1
    		99.41%
    Mal-VC-PAB-DM1 is a agent-linker conjugate for ADC with potent antitumor activity by using DM1 (a potent microtubule-disrupting agent), linked via the ADC linker Mal-VC-PAB .
    Mal-VC-PAB-DM1
  • HY-15741
    Mc-MMAE
    		99.93%
    Mc-MMAE is a protective group (maleimidocaproyl)-conjugated monomethyl auristatin E (MMAE), which is a potent tubulin inhibitor. Mc-MMAE is a agent-linker conjugate for ADC.
    Mc-MMAE
  • HY-101141
    sulfo-SPDB-DM4
    		99.97%
    sulfo-SPDB-DM4 is a agent-linker conjugate for ADC by using the maytansinebased payload (DM4, an antitubulin agent) via the sulfo-SPDB linker.
    sulfo-SPDB-DM4
  • HY-136317
    MC-betaglucuronide-MMAE-1
    		99.23%
    MC-betaglucuronide-MMAE-1 is a agent-linker conjugate for ADC with potent antitumor activity by using MMAE (a tubulin polymerization inhibitor), linked via the cleavable ADC linker MC-betaglucuronide.
    MC-betaglucuronide-MMAE-1
  • HY-130990
    DBCO-PEG4-Val-Cit-PAB-MMAF
    		98.69%
    DBCO-PEG4-Val-Cit-PAB-MMAF consists a cleavable 4 unit PEG ADC linker (DBCO-PEG4-Val-Cit-PAB) and a potent tubulin polymerization inhibitor (MMAF). DBCO-PEG4-Val-Cit-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). DBCO-PEG4-Val-Cit-PAB-MMAF is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Val-Cit-PAB-MMAF
  • HY-131056
    Gly3-VC-PAB-MMAE
    		99.63%
    Gly3-VC-PAB-MMAE consists a cleavable ADC linker (Gly3-VC-PAB) and a potent tubulin inhibitor (MMAE). Gly3-VC-PAB-MMAE can be used in the synthesis of antibody-drug conjugates (ADCs).
    Gly3-VC-PAB-MMAE
  • HY-147239
    MC-VA-PABC-MMAE
    		99.93%
    MC-VA-PABC-MMAE is a agent-linker conjugate for ADC. MC-VA-PABC-MMAE contains the ADCs linker (peptide MC-VA-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162).
    MC-VA-PABC-MMAE
  • HY-139642
    Mal-(CH2)5-Val-Cit-PAB-Eribulin
    		99.82%
    Mal-(CH2)5-Val-Cit-PAB-Eribulin is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-microtubule agent, Eribulin, linked via linker Mal-(CH2)5-Val-Cit-PAB.
    Mal-(CH2)5-Val-Cit-PAB-Eribulin
  • HY-128968
    PEG4-aminooxy-MMAF
    		99.83%
    PEG4-aminooxy-MMAF is a agent-linker conjugate for ADC with potent antitumor activity by using the potent antitubulin agent MMAF, linked via the noncleavable PEG4.
    PEG4-aminooxy-MMAF
  • HY-126350
    CL2-SN-38
    		99.23%
    CL2-SN-38 is a cleavable linker-based agent-Linker conjugate, it can conjugate with the anti-Trop-2-humanized antibody hRS7. CL2-SN-38 can be used for the reasearch of cancer.
    CL2-SN-38
  • HY-126690
    DBCO-(PEG2-VC-PAB-MMAE)2
    		99.21%
    DBCO-(PEG2-VC-PAB-MMAE)2 is made by MMAE conjugated to the cleavable DBCO-(PEG2-VC-PAB)2 linker. Monomethyl auristatin E (MMAE), a potent tubulin inhibitor, is a toxin payload in antibody agent conjugate. DBCO-(PEG2-VC-PAB-MMAE)2 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-(PEG2-VC-PAB-MMAE)2
  • HY-155870A
    DL-01 formic
    		98.46%
    DL-01 formic is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
    DL-01 formic
  • HY-141156
    Mal-PEG8-Val-Cit-PAB-MMAE
    		98.10%
    Mal-PEG8-Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Mal-PEG8-Val-Cit-PAB-MMAE contains a cleavable ADC linker and a potent tubulin inhibitor MMAE (HY-15162).
    Mal-PEG8-Val-Cit-PAB-MMAE
  • HY-101162
    SGD-1910
    SGD-1910 is a agent-linker conjugate for ADC by using the antitumor antibiotic, pyrrolobenzodiazepine (PBD, a cytotoxic DNA crosslinking), linked via the cleavable linker MC-Val-Ala.
    SGD-1910
  • HY-128957
    Vc-seco-DUBA
    		99.95%
    Vc-seco-DUBA (SYD985) is a agent-linker conjugate for ADC with potent antitumor activity by using DUBA (DNA alkylating agent), linked via the ADC linker Vc-seco.
    Vc-seco-DUBA
  • HY-13631F
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride
    		99.89%
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan, as a drug-linker conjugate composed of linker Gly-Gly-Phe-Gly-NH-O-CO and Exatecan, can be used to prepare antibody conjugate drugs. Exatecan is a DNA topoisomerase I inhibitor that can be used in cancer research.
    Gly-Gly-Phe-Gly-NH-O-CO-Exatecan hydrochloride
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.